Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women.

Abstract:

:Dienogest offers pharmacological advantages for the effective treatment of endometriosis and for use in contraception and hormone replacement therapy. This pharmacodynamic study investigated the ovulation-inhibiting effects of dienogest monotherapy in healthy women. Dienogest was administered at 0.5, 1, 2, or 3 mg daily for up to 72 days to women aged 18 to 35 years (n = 102). Ovarian activity was assessed pretreatment and during 2 treatment periods (days 0-36 and days 37-72) by the Hoogland score, based on follicle size and serum estradiol and progesterone levels. Additional hormonal parameters and endometrial thickness were assessed. Hoogland scoring indicated ovulation in all women pretreatment, decreasing to 3 of 21, 1 of 23, 0 of 20, and 0 of 23 women in the 0.5-, 1-, 2-, and 3-mg groups, respectively (per-protocol set). Maximum serum estradiol concentrations were similar to pretreatment levels in the 0.5- or 1-mg group and decreased moderately (within physiologic levels) in the 2- or 3-mg group. Endometrial thickness was reduced by all dienogest doses. Hormonal changes during follow-up indicated resumption of ovulation in most women, shortly after treatment cessation. Dienogest ≥2 mg daily provides moderate suppression of estradiol production and reliable ovulation inhibition, which reverses rapidly after treatment cessation.

journal_name

J Clin Pharmacol

authors

Klipping C,Duijkers I,Remmers A,Faustmann T,Zurth C,Klein S,Schuett B

doi

10.1177/0091270011423664

subject

Has Abstract

pub_date

2012-11-01 00:00:00

pages

1704-13

issue

11

eissn

0091-2700

issn

1552-4604

pii

0091270011423664

journal_volume

52

pub_type

杂志文章,随机对照试验
  • Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers.

    abstract::This study was designed to determine the pharmacokinetics and dose proportionality of clentiazem (CLZ) after single doses (SD) of 20, 40, and 80 mg and multiple dose administration (SS) of 40, 80, and 160 mg/day for 5 days. The study was an open-label, randomized four-period complete crossover design. Twenty-four heal...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1993.tb04684.x

    authors: Bhargava VO,Shah AK,Weir SJ,Nordbrock EE,Giesing DH

    更新日期:1993-05-01 00:00:00

  • Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes.

    abstract::This multi-center, randomized, double-blind, multiple dose-escalation study was conducted to assess the pharmacokinetics and pharmacodynamics of a newly developed polyethylene glycol (PEG)-conjugated glucagon-like peptide-1 (GLP-1) receptor agonist, PEX168 once weekly in Chinese patients with type 2 diabetes (T2DM). F...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1002/jcph.386

    authors: Yang GR,Zhao XL,Jin F,Shi LH,Yang JK

    更新日期:2015-02-01 00:00:00

  • Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.

    abstract::CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Population pharmacokinetics analyses were performed ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1366

    authors: Wang Q,Banerjee K,Vasilinin G,Marier JF,Gibbons JA

    更新日期:2019-05-01 00:00:00

  • Clinical evaluation of hypnotic drugs: contributions from sleep laboratory studies.

    abstract::The most thorough and clinically relevant approach to hypnotic drug evaluation is one that balances the strengths and weaknesses of clinical trials and sleep laboratory evaluations. Advantages of clinical trials include the ability to evaluate large numbers of subjects and specific target groups and to thoroughly asse...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1002/j.1552-4604.1979.tb02489.x

    authors: Kales A,Scharf MB,Soldatos CR,Bixler EO

    更新日期:1979-07-01 00:00:00

  • Pharmacokinetics of hydroxyethyl starch in normal subjects.

    abstract::To determine the elimination of high-molecular-weight hydroxyethyl starch (HES, Mw 450,000) in normal subjects, ten volunteers were given 500 ml 6% HES solution by intravenous infusion, and serial blood and urine samples were collected for nonglucose total carbohydrate determination. On the average, 46 and 64 per cent...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1982.tb02164.x

    authors: Yacobi A,Stoll RG,Sum CY,Lai CM,Gupta SD,Hulse JD

    更新日期:1982-04-01 00:00:00

  • Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.

    abstract::Cefprozil, a new broad-spectrum oral cephalosporin, is composed of cis and trans isomers in an approximate 90:10 ratio. The pharmacokinetics of a single oral 1000-mg dose of cefprozil were evaluated in 6 healthy subjects and 24 patients with various degrees of renal impairment. Six of these subjects were studied both ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1991.tb03719.x

    authors: Shyu WC,Pittman KA,Wilber RB,Matzke GR,Barbhaiya RH

    更新日期:1991-04-01 00:00:00

  • Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects.

    abstract::The objective of this study was to determine the effects of double-strength grapefruit juice on gastric pH and systemic bioavailability of indinavir in HIV-infected subjects receiving indinavir. Fourteen HIV-infected subjects took 800 mg of indinavir with 6 ounces (180 ml) of water or double-strength grapefruit juice....

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1177/00912700122010140

    authors: Shelton MJ,Wynn HE,Hewitt RG,DiFrancesco R

    更新日期:2001-04-01 00:00:00

  • Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer.

    abstract::The primary objective of this study was to identify intravenous regimens of tipifarnib that would mimic the systemic exposure obtained after the current twice-daily oral administration of tipifarnib. After determination of an intravenous dose that 6 subjects with advanced cancer could tolerate, another 26 subjects wer...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1177/0091270006291034

    authors: Zhang S,Zannikos P,Awada A,Piccart-Gebhart M,Dirix LY,Fumoleau P,Verhaeghe T,Francois M,De Porre P

    更新日期:2006-10-01 00:00:00

  • A bioequivalence study of oral controlled-release morphine using naltrexone blockade.

    abstract::Twenty-three normal volunteers who received morphine sulphate (MS Contin) with naltrexone completed this randomized, analytically blinded, two-way crossover comparison of the bioavailability of one 200-mg oral controlled-release morphine sulfate tablet with two 100-mg MSC tablets. Morphine effects were blocked by thre...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1002/j.1552-4604.1995.tb04094.x

    authors: Kaiko RF,Grandy RP,Reder RF,Goldenheim PD,Sackler RS

    更新日期:1995-05-01 00:00:00

  • Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.

    abstract::Acute asthma exacerbations are primarily due to airway inflammation and remain one of the most frequent reasons for childhood hospitalizations. Although systemic corticosteroids remain the mainstay of therapy because of their anti-inflammatory properties, not all inflammatory pathways are responsive to systemic cortic...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.1738

    authors: Arnold DH,Van Driest SL,Reiss TF,King JC,Akers WS

    更新日期:2021-03-01 00:00:00

  • The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene.

    abstract::The disposition of nalmefene, an opioid antagonist intended for the reversal of opioid-induced respiratory depression, and its primary metabolite nalmefene glucuronide, were characterized in adult volunteers with normal renal function and in patients with end-stage renal disease (ESRD). The effect of hemodialysis on t...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1996.tb04179.x

    authors: Matzke GR,Frye RF,Alexander AC,Reynolds R,Dixon R,Johnston J,Rault RM

    更新日期:1996-02-01 00:00:00

  • Specificity of renal tubular damage criteria for aminoglycoside nephrotoxicity in critically ill patients.

    abstract::Two populations of critical care patients were studied using indices of renal tubular damage (beta 2-microglobulin, enzymes, casts) and indices of glomerular filtration (creatinine, creatinine clearance). The purpose of these studies had been initially to elucidate the type of renal failure typical of the critically i...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1983.tb01793.x

    authors: Schentag JJ

    更新日期:1983-10-01 00:00:00

  • Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects.

    abstract::This analysis was conducted to characterize the pharmacokinetics and pharmacodynamics of pegfilgrastim and to develop a pharmacokinetic-pharmacodynamic model to describe the granulopoietic effects of pegfilgrastim and the homeostatic regulation of pegfilgrastim clearance in healthy subjects. Pegfilgrastim serum concen...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270006288731

    authors: Roskos LK,Lum P,Lockbaum P,Schwab G,Yang BB

    更新日期:2006-07-01 00:00:00

  • Efficacy and duration of action of procaterol, a new bronchodilator.

    abstract::Procaterol, a new beta-adrenergic agonist, was tested in two different doses in patients with reversible airway obstruction. Single oral doses of 0.05 or 0.1 mg produce an increase in measured expiratory flow rates, and the peak and duration of action are both dose related. Side effects reported during this one-day st...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1982.tb02669.x

    authors: Zanetti CL,Rotman HH,Dresner AJ

    更新日期:1982-05-01 00:00:00

  • Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents.

    abstract::The primary objective was to determine the pharmacokinetics of single oral and intravenous doses of pantoprazole in children 2 to 16 years of age. The secondary objective was to assess the safety and tolerability of these doses. Male and female hospitalized and nonhospitalized patients from ages 5 to 16 years received...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1177/0091270008321811

    authors: Kearns GL,Blumer J,Schexnayder S,James LP,Adcock KG,Reed MD,Daniel JF,Gaedigk A,Paul J

    更新日期:2008-11-01 00:00:00

  • Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

    abstract::Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ATR-107, a fully human monoclonal anti-IL-21 receptor (IL-21R) antibody, administered as ascending single doses, subcutaneously or intravenously, was evaluated in a placebo-controlled, double-blind trial in healthy subjects. The dose levels were...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/jcph.158

    authors: Hua F,Comer GM,Stockert L,Jin B,Nowak J,Pleasic-Williams S,Wunderlich D,Cheng J,Beebe JS

    更新日期:2014-01-01 00:00:00

  • The effect of multiple doses of peginterferon alfa-2b on the steady-state pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy.

    abstract::This multicenter, open-label study evaluated the effects of multiple doses of peginterferon alfa-2b on the steadystate pharmacokinetics of methadone in 20 adults with hepatitis C virus infection who were enrolled in a methadone maintenance program. All subjects received peginterferon alfa-2b 1.5 mug/kg/wk for 4 weeks ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1177/0091270007299760

    authors: Gupta SK,Sellers E,Somoza E,Angles L,Kolz K,Cutler DL

    更新日期:2007-05-01 00:00:00

  • Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab.

    abstract::Categorizations of best response observed at week 8 (between week 3 and 14) of first-line treatment in two studies of bevacizumab plus chemotherapy in Western (878 patients) and Chinese (198 patients) patients with non-small cell lung cancer were assessed together with baseline prognostic factors in multivariate param...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.191

    authors: Claret L,Gupta M,Han K,Joshi A,Sarapa N,He J,Powell B,Bruno R

    更新日期:2014-03-01 00:00:00

  • Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.

    abstract::The authors examined the pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in 17 patients (4 children, 13 adults) with B-lineage lymphoid malignancies, including 12 patients with acute lymphoblastic leukemia (ALL) and 5 patients with non-Hodgkin's lymphoma (NHL). The immunoconjugat...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1177/00912709922012051

    authors: Chen CL,Levine A,Rao A,O'Neill K,Messinger Y,Myers DE,Goldman F,Hurvitz C,Casper JT,Uckun FM

    更新日期:1999-12-01 00:00:00

  • Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations.

    abstract::Antibacterial drugs are among the most common medications used by pregnant women. While medical literature generally defines nitrofurantoin as an antibiotic that is safe for use during the first trimester of pregnancy, new concerns about a possible association between congenital malformations following exposure to nit...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/jcph.139

    authors: Goldberg O,Koren G,Landau D,Lunenfeld E,Matok I,Levy A

    更新日期:2013-09-01 00:00:00

  • A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.

    abstract::The chemoattractant receptor-homologous molecule expressed on T-helper 2 cells (CRTH2) is a G-protein-coupled receptor for prostaglandin D2 , a key mediator in inflammatory disorders. In this randomized, double-blind, placebo-controlled study we investigated the single- and multiple-dose tolerability, pharmacokinetics...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1002/jcph.478

    authors: Géhin M,Strasser DS,Zisowsky J,Farine H,Groenen PM,Dingemanse J,Sidharta PN

    更新日期:2015-07-01 00:00:00

  • A pharmacological analysis of levonantradol antinociception in mice.

    abstract::Using the hot plate test, the potency and mechanism of the analgesic activity of levonantradol was studied in mice. Levonantradol is 10 to 30 times more potent than morphine; the antinociception can be only partially blocked by naloxone. Similar limited antagonism by cholinergics indicates possible opiodergic mechanis...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1981.tb02611.x

    authors: Jacob JJ,Ramabadran K,Campos-Medeiros M

    更新日期:1981-08-01 00:00:00

  • Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients.

    abstract::Cyclosporin G (CSG) has produced less nephrotoxicity than cyclosporin A (CSA) at equivalent doses in animal models. Conflicting results have been reported concerning differences in the pharmacokinetics of CSA and CSG in preclinical studies, and no data exist regarding the effect of steady-state oral administration of ...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1002/j.1552-4604.1997.tb04339.x

    authors: Gruber SA,Gallichio M,Rosano TG,Kaplan SS,Hughes SE,Urbauer DL,Singh TP,Lempert N,Conti DJ,Stein DS,Drusano G

    更新日期:1997-07-01 00:00:00

  • Pharmacology and pharmacokinetics of amiodarone.

    abstract::Amiodarone is a unique antiarrhythmic agent originally developed as a vasodilator. Classified electrophysiologically as a Type III antiarrhythmic, it also has both nonspecific antisympathetic and direct, fast channel-membrane effects. Hemodynamic effects of orally administered amiodarone (a negative inotropic agent) a...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1991.tb03673.x

    authors: Freedman MD,Somberg JC

    更新日期:1991-11-01 00:00:00

  • Safety, tolerability, QTc evaluation, and pharmacokinetics of single and multiple doses of enzastaurin HCl (LY317615), a protein kinase C-beta inhibitor, in healthy subjects.

    abstract::The safety, tolerability, and pharmacokinetics of orally administered enzastaurin were evaluated in 2 placebo-controlled, dose escalation studies in healthy subjects. In the first human dose study, single doses (2-400 mg) were evaluated, with 22 subjects receiving enzastaurin. The mean half-lives of enzastaurin and it...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1177/0091270007304775

    authors: Welch PA,Sinha VP,Cleverly AL,Darstein C,Flanagan SD,Musib LC

    更新日期:2007-09-01 00:00:00

  • Blood pressure response to a single daily dose of a clonidine-chlorthalidone combination.

    abstract::A single evening dose of a clonidine-chlorthalidone combination (Combipres) was compared with the usual twice-daily schedule in 11 patients with essential hypertension. No significant difference was found between the blood pressures recorded on the two regimens or between morning and afternoon pressures on the once-da...

    journal_title:Journal of clinical pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1002/j.1552-4604.1980.tb01695.x

    authors: Grossman SH,Gunnells JC

    更新日期:1980-04-01 00:00:00

  • Effect of unbound clearance on binding parameters of valproic acid to serum proteins.

    abstract::Nine healthy subjects received 400 mg sodium valproate orally in the fasting state. Binding parameters of valproic acid to serum proteins were determined by Scatchard analysis for individual series of valproic acid data. Total and unbound (intrinsic) clearances (CLt and CLu) were calculated by dividing the dose by the...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1993.tb03932.x

    authors: Kodama Y,Tsutsumi K,Teraoka I,Fujii I,Takeyama M

    更新日期:1993-02-01 00:00:00

  • Intense surveillance of adverse drug reactions. An analysis of 338 patients.

    abstract::A prospective study of adverse drug reactions was recently completed at the Clinical Pharmacology Unit of J. J. Group of Hospitals. 338 patients were included in this study, and adverse reactions were noted by a team of workers including a nurse and a physician. World Health Organization definitions were used to descr...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1002/j.1552-4604.1975.tb02365.x

    authors: Vakil BJ,Kulkarni RD,Chabria NL,Chadha DR,Deshpande VA

    更新日期:1975-05-01 00:00:00

  • Clinical utility of ambulatory blood pressure monitoring in target organ complications and equipment choices.

    abstract::Although population studies have demonstrated a relationship between casual office blood pressures and target organ events, the variability of these blood pressure measurements for individual patients has generated an interest in the role of ambulatory blood pressure monitoring for defining the presence of hypertensio...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/j.1552-4604.1992.tb05771.x

    authors: Prisant LM,Bottini PB,Carr AA

    更新日期:1992-07-01 00:00:00

  • Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies.

    abstract::Glomerular filtration rate (GFR) is routinely used as a surrogate endpoint for the development of investigational drugs in clinical trials. GFR and staging of chronic kidney disease are typically assessed by measuring the concentration of endogenous serum biomarkers such as albumin and creatinine. However, creatinine ...

    journal_title:Journal of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1002/jcph.1132

    authors: Kar S,Paglialunga S,Islam R

    更新日期:2018-10-01 00:00:00